Why the study?
This study sought to evaluate how age, anaemia, impaired renal function, and concomitant therapy are associated with DOAC-related outcomes in patients aged 60 years and older with multimorbidity and polypharmacy.
Are age, anaemia, impaired renal function, and concomitant therapy associated with DOAC-related complications and treatment interruption in patients aged 60 years and older with non-valvular atrial fibrillation, multimorbidity, and polypharmacy?
Cohort (n=503)
No
Are age, anaemia, impaired renal function, and concomitant therapy associated with DOAC-related complications and treatment interruption in patients aged 60 years and older with non-valvular atrial fibrillation, multimorbidity, and polypharmacy?
Answers are grounded in this paper and cite their sources.
In older patients with non-valvular atrial fibrillation, multimorbidity, and polypharmacy, age 70 years and older is associated with a significantly higher rate of DOAC treatment interruption compared to patients aged 60 to 69 years.
Objective. To assess the association of age, anaemia, impaired renal function and concomitant therapy with direct oral anticoagulant (DOAC)-related outcomes in patients aged 60 years and older with multimorbidity and polypharmacy. Material and methods. This prospective single-centre study included 503 patients aged 60 years and older receiving DOACs for non-valvular atrial fibrillation in the geriatric, internal medicine and cardiology departments of Moscow War Veterans Hospital No.2 from April 2023 to September 2024. Polypharmacy was defined as the concomitant use of five or more medications. Treatment interruption, haemorrhagic complications, DOAC switching, and a composite measure of uninterrupted treatment without recorded complications were assessed. Results. Treatment interruption was more frequent in patients aged 70 years and older than in those younger than 70 years (42.0% vs 18.5%; p=0.009). Patients with creatinine clearance
No takes yet. Share an insight, caveat, or question.
Kondrakhin et al. (2026) conducted a cohort in Non-valvular atrial fibrillation with multimorbidity and polypharmacy (n=503). Age ≥70 years (alongside anaemia, impaired renal function, and concomitant therapy) vs. Age <70 years was evaluated on Treatment interruption (assessed alongside haemorrhagic complications, DOAC switching, and uninterrupted treatment without recorded complications) (p=0.009).
Synapse has enriched 10 related papers. Consider them for comparative context: